爱尔兰爵士制药的去纤维钠安全性如何？

Sir Irish Pharmaceuticals is a polydeoxyribonucleic acid salt that has certain fibrinolytic and anti-thrombotic activities and can promote the production of prostacycline-like substances and release them from vascular tissues into the circulation. This medicine is indicated for the treatment of adult and pediatric patients with hepatic venous occlusion (VOD) and associated renal or pulmonary abnormalities after blood or bone marrow hematopoietic stem cell transplantation (HSCT).

The recommended dose of Irish Jazz Pharmaceuticals' defibrinated sodium for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Defibrotide must be diluted prior to infusion. Prior to administration of defibrinated sodium, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.

How safe is Irish Jazz Pharmaceuticals' defibrinated sodium?

The effectiveness of Irish Jazz Pharmaceuticals was evaluated through 3 research trials conducted on 528 patients. The subjects participating in the 3 trials were all patients diagnosed with VOD symptoms after HSCT and accompanied by abnormal liver or kidney function. The overall survival rate 100 days after HSCT was used as the indicator. As an evaluation indicator, the results showed that the survival rate after 100 days of defibrotide treatment was 38% to 45%; while data analysis found that the survival rate of HSCT patients who were expected to receive only supportive care or other drug intervention after 100 days was only 21% to 31%.

Recommended related hot articles: /newsDetail/92898.html